CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 董事長兼執行董事 楊建宇 中華人民共和國北京，2025年1月6日 於本通告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii) 非執行董事王雷先生、陳宏章先生及施波濤先生；及(iii)獨立非執行董事李雪梅女士、 孫延生先生及吳國賢先生。 – 1 – 1. 審議及批准建議採納H股激勵計劃。 2. 審議及批准建議授權董事會及╱或授權人士辦理H股激勵計劃有關事宜。 臨時股東大會通告 茲通告美中嘉和醫學技術發展集團股份有限公司（「本公司」）謹訂於2025年1月22 日（星期三）上午九時正假座中國北京市朝陽區光華路7號漢威大廈東區26樓A1室舉行 臨時股東大會，以審議及酌情通過以下決議案。除文義另有所指外，本通告所用詞彙 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券交 易商、銀行經理、律師、專業會計師或其他專業顧問。 倘 閣下已出售或轉讓名下所有美中嘉和醫學技術發展集團股份有限公司的股份，應立即將本通函 連同隨附之代表委任表格送交買方或承讓人，或經手買賣或轉讓之持牌證券交易商或註冊證券機構 或其他代理人，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） (1)建議採納H股激勵計劃； (2)建議授權董事會及╱或授權人士 辦理H股激勵計劃有關事宜； 及 (3)臨時股東大會通告 董事會函件載於本通函第5至14頁。 美中嘉和醫學技術發展集團股份有限公司將於2025年1月22日（星期三）上午九時正假座中國北京 市朝陽區光華路7 ...

建議採納H股激勵計劃 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 建議採納H股激勵計劃 建議授權董事會及╱或授權人士 辦理H股激勵計劃有關事宜 及 暫停辦理股份過戶登記手續 為確保H股激勵計劃的成功實施，董事會建議，在股東於臨時股東大會上批准H股 激勵計劃的前提下，股東亦應授權董事會及╱或授權人士全權處理若干H股激勵 計劃有關事宜，授權詳情將於通函載列。 臨時股東大會 根據本公司組織章程細則，H股激勵計劃及相關事宜須由（其中包括）股東於本公 司股東大會批准。建議採納H股激勵計劃及建議授權董事會及╱或授權人士辦理 H股激勵計劃有關事宜須待股東於臨時股東大會上以特別決議案批准。 本公司將召開臨時股東大會以審議及酌情批准（其中包括）建議採納H股激勵計劃 及建議授權董事會及╱或授權 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453) 自願公告 重要合作協議 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」）董事會（「董事會」）自願刊發。 董事會欣然宣佈，近期，本公司與妙佑醫學教育和研究基金會（Mayo Foundation for Medical Education and Research）（「妙佑醫療國際」）已訂立合作協議（「協 議」），據此，妙佑醫療國際同意向本集團提供有關組織目標及臨床實踐的諮詢服 務（「合作」）。協議期限為三(3)年。 董事會謹此強調，合作的實施構成雙方之間長期合作的基礎，此項合作須待簽立 明確的工作說明書後方可作實。根據自簽立日期起計的首個年度的工作說明書， 合作將聚焦於改進本集團醫院項目臨床 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 訂立融資租賃協議 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」）董事會（「董事會」）自願刊發。 董事會欣然宣佈，為增加本集團日常營運資金，於2024年12月17日，本公司與中 關村科技租賃股份有限公司（「中關村科技租賃」）經公平磋商後訂立融資租賃協議 （「該協議」），據此，中關村科技租賃同意以售後回租若干醫療設備的方式向本公 司提供融資租賃服務，融資租賃本金總額不超過人民幣200百萬元。該協議的期 限為四年。本公司控股股東，即醫學之星（上海）企業管理有限公司（「上海醫學之 星」）及楊建宇博士（「楊博士」），將向中關村科技租賃提供擔保，作為融資租賃的 抵押（「擔保」）。 中關村科技租賃為一家根據中國法律註冊成立的股份有限公司，其H股在聯交所 上市， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 董事會欣然宣佈，中華人民共和國國家藥品監督管理局亦已於2024年12月6日批 准本公司設備供應商的質子治療設備醫療器械註冊證的註冊申請。 1 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 有關質子治療設備醫療器械註冊證的註冊申請的批准 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」）董事會（「董事會」）自願刊發。 茲提述本公司日期為2023年12月29日的招股章程（「招股章程」）、日期為2024年 3月27日的截至2023年12月31日止年度的年度業績公告、日期為2024年4月19日 的2023年年報、日期為2024年8月29日的截至2024年6月30日止六個月的中期業 績公告及日期為2024年9月14日有關質子治療服務的業 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 附屬公司註冊股本增加 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」）董事會（「董事會」）自願刊發。 北京和信康為一家以人工智能為導向的公司。本公司將繼續投資人工智能領域， 期待與更多商業夥伴共同推動人工智能醫療技術的蓬勃發展。有關北京和信康業 務的更多資料，請參閱本公司日期為2023年12月29日的招股章程「歷史、發展及 公司架構－收購、投資及處置－收購北京和信康」。 本公司股東及有意投資者於買賣本公司股份時，務請審慎行事。 承董事會命 董事會欣然宣佈，於2024年11月25日，本公司控股的附屬公司北京和信康科技 有限公司已與其現任股東（包括本公司及和信康投資控股有限公司（「 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會謹此補充以下有關全球發售所得款項淨額（「首次公開發售所得款項」）用途 的額外資料。 上市所得款項淨額用途 誠如中期業績公告及中期報告所披露，截至2024年6月30日，本公司持有9家不同 基金公司的9款保本低風險金融產品（以下簡稱「該等投資」）作資金管理用途，其 公允價值合計為人民幣207.2百萬元。該等投資可按要求贖回。 誠如招股章程所披露，倘所得款項淨額並未即時應用於上述用途，本公司會將所 得款項淨額存入持牌銀行或證券及期貨條例或中國適用法律及法規所界定的其他 認可金融機構作為短期活期存款，惟其被視為符合本公司的最佳利益。考慮到該 等投資為短期、保本及可按要求贖回，因此首次公開發售所得款項可按招股章程 所載披露的方式及時贖回並應用，本公司誤解該 ...

Clinical and Technological Developments - The company successfully completed clinical trials for its proton therapy equipment at Guangzhou Hospital, with the National Health Commission approving its Class A large medical equipment configuration license on September 13, 2024[12]. - The cloud imaging platform underwent significant upgrades, including the addition of a cloud PACS module, enhancing market competitiveness and achieving record monthly active users for the remote imaging diagnostic platform[13]. - The AI business made notable progress, obtaining registration for a Class II medical device for 3D visualization software and commercializing AI-related software, generating sales revenue in the brain disease screening and diagnosis sector[14]. - The company’s research achievements were recognized internationally, with a paper published in the authoritative journal BMC Surgery, enhancing its academic reputation[11]. - The company’s innovative research on particle therapy was well-received at the 62nd International Particle Therapy Co-Operative Group Annual Meeting, contributing to global advancements in radiation therapy technology[11]. - The company has developed a new invention patent related to a health data processing system, further solidifying its expertise in the medical AI field[15]. Market Expansion and Business Strategy - The company plans to actively explore new markets and innovative business models, including customized services, to expand market share and enhance competitiveness in the second half of 2024[13]. - The company is collaborating with well-known insurance institutions to enhance overseas medical service support and is exploring deep integration of specialty treatment with insurance products[16]. - The company launched cost-effective health screening packages targeting corporate clients, leveraging competitive pricing and geographical advantages to attract more clients in the second half of 2024[16]. - The company is exploring potential acquisitions to enhance its service portfolio and market share, with a target completion date by the end of 2024[165]. - A strategic partnership with a leading technology firm has been established to develop AI-driven healthcare solutions, expected to launch in early 2025[165]. Financial Performance and Position - Revenue for the six months ended June 30, 2024, was RMB 218,988 thousand, a decrease of 23.2% compared to RMB 285,179 thousand for the same period in 2023[100]. - Cost of revenue for the same period was RMB (253,500) thousand, down from RMB (320,151) thousand, reflecting a reduction of 20.8%[100]. - Gross loss for the six months was RMB (34,512) thousand, slightly improved from RMB (34,972) thousand in the previous year[100]. - Total loss for the period attributable to owners of the company was RMB (181,876) thousand, compared to RMB (194,276) thousand in the prior year, a decrease of 6.3%[100]. - The company reported a total comprehensive loss of RMB 194,276 thousand for the six months ended June 30, 2024, compared to a loss of RMB 181,876 thousand for the same period in the previous year[103]. - The company reported a loss attributable to owners of RMB 181.8 million and a net current liability of RMB 609.0 million[112]. - The company reported a decrease in operating cash flow to RMB (178,601) thousand, compared to RMB (130,587) thousand in the previous year, reflecting a decline in operational performance[105]. - The company recognized a gain from the sale of a subsidiary amounting to RMB 36,889 thousand, which was not present in the previous year, indicating strategic divestment activities[105]. Cash Flow and Capital Management - Cash and cash equivalents decreased by 56.7% from RMB 257.3 million as of June 30, 2023, to RMB 111.5 million as of June 30, 2024, mainly due to cash used in investing activities[44]. - Net cash used in operating activities for the six months ended June 30, 2024, was RMB 178.8 million, an increase of RMB 48.1 million compared to RMB 130.7 million for the same period in 2023[45]. - Net cash used in investing activities increased significantly to RMB 464.3 million for the six months ended June 30, 2024, from RMB 4.4 million for the same period in 2023, primarily due to investments in a joint venture and purchases of financial assets[46]. - Net cash generated from financing activities increased to RMB 714.1 million for the six months ended June 30, 2024, compared to RMB 265.9 million for the same period in 2023, mainly due to proceeds from a global offering[46]. - The company plans to fully utilize the net proceeds from the global offering by December 31, 2025, subject to business needs and market conditions[75]. Corporate Governance and Shareholder Information - The company has adopted corporate governance principles to enhance transparency and accountability to shareholders[76]. - The company will continue to review and monitor its corporate governance practices regularly to ensure compliance[76]. - The company is committed to effective internal control measures as part of its corporate governance framework[76]. - The company has disclosed the interests of its directors and senior executives in shares and related securities as required by the Securities and Futures Ordinance[79]. - The company aims to maintain good corporate governance practices since its listing date[76]. Employee and Operational Metrics - The company had 691 employees as of June 30, 2024, down from 765 employees a year earlier[62]. - The total employee costs for the six months ended June 30, 2024, were approximately RMB 116.54 million[62]. - Administrative expenses decreased to RMB (79,090) thousand from RMB (93,536) thousand, a reduction of 15.5%[100]. - Research and development expenses were reduced to RMB (14,128) thousand from RMB (18,518) thousand, a decrease of 23.5%[100]. - The company has implemented cost-control measures that are projected to reduce operational expenses by 5% in the next fiscal year[165].

Financial Performance - Revenue decreased by 23.2% from RMB 285.2 million for the six months ended June 30, 2023, to RMB 219.0 million for the six months ended June 30, 2024[1]. - Gross loss slightly decreased by 1.4% from RMB 35.0 million to RMB 34.5 million during the same period[1]. - Net loss reduced by 5.7% from RMB 214.3 million to RMB 202.0 million[1]. - Adjusted net loss (non-HKFRS measure) decreased by 24.7% from RMB 214.0 million to RMB 161.1 million[1]. - Revenue for the six months ended June 30, 2024, was RMB 218,988 thousand, a decrease of 23.3% compared to RMB 285,179 thousand for the same period in 2023[61]. - The net loss for the six months ended June 30, 2024, was RMB (202,019) thousand, compared to a net loss of RMB (214,257) thousand for the same period in 2023, indicating a 5.7% improvement[61]. - Basic and diluted loss per share for the period was RMB (0.25), an improvement from RMB (0.30) in the previous year[61]. - For the six months ended June 30, 2024, the company reported a loss attributable to owners of RMB 181.9 million, compared to a loss of RMB 194.3 million for the same period in 2023[67]. Revenue Breakdown - Hospital business revenue fell by 13.4% from RMB 159.3 million to RMB 137.8 million, primarily due to adjustments in revenue structure and focus on proton business development[13]. - Revenue from medical equipment, software, and related services dropped by 35.6% from RMB 125.9 million to RMB 81.1 million, attributed to decreased demand and anti-corruption policies in the medical industry[14]. - Sales and installation of medical equipment and software revenue decreased by 29.8% from RMB 104.3 million to RMB 73.2 million[14]. - Revenue from customer contracts was RMB 213.15 million for the six months ended June 30, 2024, a decrease of 22.6% from RMB 275.59 million in the prior year[70]. Cash Flow and Financial Position - Cash and cash equivalents decreased by 56.7% from RMB 2,573 million as of June 30, 2023, to RMB 1,115 million as of June 30, 2024, primarily due to cash used in investing activities[37]. - Net cash used in operating activities increased to RMB 178.8 million for the six months ended June 30, 2024, from RMB 130.7 million for the same period in 2023, mainly due to a decrease in overall revenue[38]. - Net cash used in investing activities increased significantly to RMB 464.3 million for the six months ended June 30, 2024, from RMB 4.4 million for the same period in 2023, primarily due to investments in a joint venture and purchases of financial assets[38]. - Net cash generated from financing activities increased to RMB 714.1 million for the six months ended June 30, 2024, from RMB 265.9 million for the same period in 2023, mainly due to proceeds from the global offering[38]. - Current liabilities increased from approximately RMB 1,204.5 million as of December 31, 2023, to approximately RMB 1,286.2 million as of June 30, 2024, primarily due to increased bank borrowings and accrued expenses[36]. - The company's net current liabilities as of June 30, 2024, were RMB 609.0 million, compared to RMB 844.7 million as of December 31, 2023, mainly due to proceeds from the global offering[43]. Operational Highlights - Guangzhou Hospital has treated over 90,000 cancer patients and performed over 2,000 surgeries since its opening, establishing itself as a leading institution in the Greater Bay Area[3]. - Guangzhou Hospital has trained nearly 160 proton therapy professionals for around 50 medical institutions and research institutes across the country[3]. - The hospital received three awards from the China Anti-Cancer Association, highlighting its leadership in cancer treatment and research[3]. - The company participated in a national key research and development program for innovative radiotherapy equipment, enhancing its role in the advancement of radiotherapy technology[5]. - The hospital's research on a new particle therapy patient planning quality check method received widespread acclaim at the 62nd International Particle Therapy Co-Operative Group meeting[5]. - The company successfully hosted the "Taihe Proton Academic Exchange Conference," focusing on proton therapy for breast cancer, further solidifying its leadership in this field[5]. Strategic Initiatives - The company aims to enhance its core medical capabilities and establish a strong brand image in the oncology treatment sector[11]. - Future strategies include focusing on cloud platforms, AI, and big data technologies to empower grassroots hospitals[11]. - The company plans to develop new AI products to meet comprehensive hospital and physician needs[11]. - Continuous improvement in ESG management will be pursued to align with high-quality development and sustainable growth[11]. Share Capital and Governance - The total issued share capital increased to 716,338,000 shares from 676,918,000 shares as of December 31, 2023, representing a growth of approximately 5.8%[77]. - The company issued 39,420,000 new shares at a price of HKD 14.28 per share on January 9, 2024, raising approximately RMB 517,886,000 (equivalent to about HKD 562,920,000) in total proceeds[78]. - The company has maintained a public float of approximately 16.73% since its listing on January 9, 2024[57]. - The company has complied with the corporate governance code since its listing date[58]. - The company is committed to adhering to the corporate governance code as outlined in the listing rules, ensuring transparency and accountability in its operations[79]. Future Plans - The company plans to fully utilize the net proceeds from the global offering by December 31, 2025, subject to business needs and market conditions[56]. - The company plans to utilize the funds raised from the new share issuance for further development and expansion of its medical technology services[78].